Investigation of Evolus, Inc.

Evolus, Inc. (EOLS) Misappropriated Trade Secrets     

Beginning in February 2019, Evolus began a campaign in which it promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by a Korean bioengineering company through years of clinical research.  On July 6, 2020, the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan, the U.S. manufacturer of Botox, and Medytox, the Korean manufacturer of a similar product, against Evolus, which claimed that Evolus stole trade secrets to develop Jeuveau. The ITC Judge determined that Evolus and its South Korean partner firm misappropriated the botulinum toxin and the manufacturing process that led to its development and manufacture.  As a result, the ITC Judge recommended a ten-year long ban on Evolus’ ability to import and sell Jeuveau in the United States. On this news, Evolus’ stock dropped 37% in two days to close at $3.35 on July 8, 2020 and has yet to recover.

If you purchased Evolus, Inc. (EOLS) securities between February 1, 2019 and July 6, 2020, you have legal options.  Please reach out to Robbins LLP for more information. 

Have You Lost Money In This Company?

If you would like more information about your rights and potential remedies please send us a message.

Having information at your fingertips is easier than ever. Enroll in Robbins LLP’s free investment monitoring service, Stock Watch, for notifications of corporate misconduct impacting the value of your investments, advice on how to hold corporate officers and directors accountable for their misconduct, and to receive information about class action settlements.